Biomark Capital Management’s ADMA Biologics ADMA Stock Holding History

Biomark Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$8.9M	Hold	1,433,304	–	–	99.96%	1
2018 Q2	$6.46M	Hold	1,433,304	–	–	99.88%	1
2018 Q1	$6.59M	Hold	1,433,304	–	–	99.8%	1
2017 Q4	$4.6M	Hold	1,433,304	–	–	5.12%	2
2017 Q3	$4.42M	Hold	1,433,304	–	–	5.01%	2
2017 Q2	$5.3M	Hold	1,433,304	–	–	8.68%	2
2017 Q1	$7M	Hold	1,433,304	–	–	12.68%	2
2016 Q4	$7.34M	Hold	1,433,304	–	–	15.19%	2
2016 Q3	$10.4M	Hold	1,433,304	–	–	13.73%	2
2016 Q2	$9.3M	Hold	1,433,304	–	–	11.94%	2
2016 Q1	$11.6M	Hold	1,433,304	–	–	15.93%	2
2015 Q4	$11.6M	Buy	+1,433,304	New	+$12.9M	14.08%	2

Other funds holding ADMA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Biomark Capital Management's ADMA Position: Q3 2018 in Review

Biomark Capital Management held its ADMA Biologics (ADMA) position steady in Q3 2018 at 1,433,304 shares worth $8.9M. The position accounts for 99.96% of the portfolio, ranked #1.

Biomark Capital Management first reported a position in ADMA in Q4 2015 and has held it in 12 quarters since. The position peaked at $11.6M in Q1 2016. 58 funds tracked by Wall St. Rank hold ADMA as of Q3 2018.

Biomark Capital Management held 1,433,304 shares of ADMA Biologics worth $8.9M as of Q3 2018.
Biomark Capital Management left its ADMA Biologics share count unchanged in Q3 2018.
ADMA Biologics made up 99.96% of Biomark Capital Management's portfolio in Q3 2018, its #1 holding.
Biomark Capital Management first reported a position in ADMA Biologics in Q4 2015 and has held it in 12 quarters since.
Biomark Capital Management's ADMA Biologics position peaked at $11.6M in Q1 2016.
58 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2018.

Based on Biomark Capital Management's 13F filing for Q3 2018, filed 24 Oct 2018.